Copyright investors
The Relative Strength (RS) Rating for Celldex Therapeutics (CLDX) climbed into a higher percentile Monday, as it got a lift from 70 to 73. IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database. Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. See if Celldex Therapeutics can continue to show renewed price strength and clear that threshold. Celldex Therapeutics is now considered extended and out of buy range after clearing a 24.03 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line. The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at -71%. Keep an eye out for the company's next round of numbers on or around Nov. 5. The company earns the No. 308 rank among its peers in the Medical-Biomed/Biotech industry group. argenx ADR (ARGX), Aurinia Pharmaceuticals (AUPH) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
